Overactive Bladder Treatment Market Overview
Global overactive bladder treatment market is witnessing significant growth, mainly due to the growing prevalence of the OAB condition. Overactive bladder (OAB) condition is commonly seen in patients with kidney disease, urinary tract infection, cystitis (bladder infection), or pyelonephritis (kidney infection). Also, the rising geriatric population alongside, the increasing occurrences of Parkinson’s disease, multiple sclerosis, and stroke fosters the market growth.
At the same time, there are various novel treatments and medications available to manage the overactive bladder condition, which is pushing up the market on the global platform. According to Market Research Future (MRFR), the global overactive bladder treatment market is expected to garner substantial accruals by 2023. In its recently published analysis, MRFR also asserts that the market would register a CAGR over 3.1% during the forecast period (2018–2023).
The development of innovative intravesical therapies and increasing marketing activities by pharma companies is a significant factor leading to the growth of the market. Furthermore, technological advancements in the field of overactive bladder management and advent treatment materials are fostering the market growth to an extent.
On the other hand, complications in the treatment and high cost of product developments are impeding the growth of the market, majorly. Also, prolonged approvals and stringent regulations for approvals of medicines and devices required for OAB management are projected to obstruct the market growth during the assessment period. Nevertheless, instigation of a large number of regulatory healthcare reforms and developments of methods for the improved diagnosis and treatments of OAB would support the market growth in the next few years.
Get a FREE Sample with Complete TOC By Considering the COVID-19 impact on Global Market @ https://www.marketresearchfuture.com/sample_request/6248
Overactive Bladder Treatment Market – Segments
The report is segmented into four market dynamics to widen the scope of understanding,
By Pharmacotherapy Treatment: Anticholinergics, Solifenacin, Oxybutynin, Fesoterodine, Darifenacin, Tolterodine, and Trospium, among others (Botox, Mirabegron, Neurostimulation, others).
By Non-Pharmacological Treatment: Dietary & Fluid Modifications, Behavioral Therapy, and Pelvic Floor Muscle Rehabilitation, among others.
By Disease : Idiopathic Overactive Bladder and Neurogenic Overactive Bladder, among others.
By Regions: Asia Pacific, North America, Europe, and the Rest-of-the-World.
Overactive Bladder Treatment Market – Regional Analysis
North America dominates the global overactive bladder treatments market with the largest market share. The growing prevalence of OAB, kidney diseases, and other bladder related disorders drive growth in the regional market. Also, the high per capita healthcare expenses, advances in medical science, and growing investments into R&D are factors substantiating the regional market growth. Simultaneously, the presence of a well-established healthcare system and a large number of active market players foster the growth of the overactive bladder management market in the region.
The overactive bladder treatment market in the European region stands second in terms of the size. Factors such as financial support from the government for R&D activities, and the increasing demand for novel treatments & devices to manage the OAB conditions drive the market growth in the region. Besides, rising incidences of bladder injuries are contributing to the market growth in this region, generating massive demand for the management of the condition.
The Asia Pacific overactive bladder treatment market is emerging as a profitable market, globally. Factors such as the availability of reimbursement for specific treatment options, growing prevalence of bladder overactivity, rising geriatric population drive the regional market growth. Moreover, rising healthcare expenditure and spreading awareness about overactive bladder condition & availability of its treatments foster the market growth in the region.
The increasing governmental funding alongside a vast unmet need is offering multiple growth opportunities to the market players. Besides, the availability of low-cost, quality overactive bladder management methods accelerates the market growth in the region.
Overactive Bladder Treatment Market – Competitive Analysis
Highly competitive, the overactive bladder treatment market appears to be fragmented due to the presence of several well-established players. Players acquire small yet promising companies in emerging markets, to expand their footprints. To improve their market performance, they are also adopting strategic approaches such as M&A, collaboration, and product launch. Strategies such as innovations in product and technologies create strong investment opportunities for market players. Whereas mergers & acquisitions of local manufactures by multinational companies make the market structure look more dynamic.
Overactive Bladder Treatment Market Major Players:
Players driving the global overactive bladder treatment market include Astellas Pharma Inc., Pfizer, Inc., Teva Pharmaceutical, Mylan N.V., Allergan, Plc., Endo International Plc., Hisamitsu Pharmaceutical Co., Inc., Sanofi S. A., Johnson & Johnson, Aurobindo Pharma Limited, Intas Pharmaceuticals Ltd., Medtronic Plc., Apotex Inc., Macleods Pharmaceuticals Ltd., and Cogentix Medical, Inc., among others.
Obtain Premium Research Report Details, Considering the impact of COVID-19 @ https://www.marketresearchfuture.com/reports/overactive-bladder-treatment-market-6248
Overactive Bladder Treatment Industry/Innovation/Related News:
September 05, 2019 —- Bioness, Inc. (the US), a leading global provider of advanced, clinically supported medical devices, presented its newly approved device useful in the treatments of Overactive Bladder (OAB) – – StimRouter® Neuromodulation System at the 49th International Continence Society (ICS) Annual Meeting (Sweden). Preliminary European Post-Approval Results of StimRouter® Neuromodulation System for the Treatment of Overactive Bladder can help improve the lives of patients in Europe, Australia, and the United States.
August 28, 2019 —- Unichem Laboratories Limited (India), a leading global pharmaceutical company, announced receiving the USFDA approval for its Solifenacin Succinate Tablets indicated for the treatment of overactive. These tablets are also helpful in treating the urge urinary incontinence, urgency, and urinary frequency.